Compare DGICB & FULC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | DGICB | FULC |
|---|---|---|
| Founded | 1986 | 2015 |
| Country | United States | United States |
| Employees | 851 | N/A |
| Industry | Property-Casualty Insurers | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 565.4M | 462.2M |
| IPO Year | N/A | 2019 |
| Metric | DGICB | FULC |
|---|---|---|
| Price | $17.69 | $8.00 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 8 |
| Target Price | N/A | ★ $16.38 |
| AVG Volume (30 Days) | 2.0K | ★ 1.0M |
| Earning Date | 04-23-2026 | 04-30-2026 |
| Dividend Yield | ★ 3.72% | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $2.26 | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $8.06 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $13.84 | $2.32 |
| 52 Week High | $20.30 | $15.74 |
| Indicator | DGICB | FULC |
|---|---|---|
| Relative Strength Index (RSI) | 56.64 | 52.75 |
| Support Level | $15.57 | $6.33 |
| Resistance Level | $17.80 | $8.17 |
| Average True Range (ATR) | 0.57 | 0.49 |
| MACD | 0.21 | 0.19 |
| Stochastic Oscillator | 66.75 | 95.73 |
Donegal Group Inc is an insurance holding company that offers businesses and individuals personal and commercial lines of property and casualty insurance. The company's reportable segments are its Investment function, Personal lines of insurance, and Commercial lines of insurance. Personal lines products consist mainly of homeowners and private passenger automobile policies. The Commercial lines products of its insurance subsidiaries consist mainly of commercial automobile, commercial multi-peril, and workers' compensation policies. The group mainly operates in the United States.
Fulcrum Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing small molecules for genetically defined rare diseases. Its product candidate, Pociredir, is an oral small molecule designed to induce fetal hemoglobin (HbF) and is in clinical development for sickle cell disease (SCD). The company completed dosing in the Phase 1b PIONEER trial evaluating pociredir in adults with SCD and reported clinical data showing clinically relevant HbF induction and improvements in markers of hemolysis and anemia. The company has also generated a pipeline of clinical-stage and pre-clinical programs targeting the root causes of rare genetic diseases.